-
Taysha Pipeline, This includes their TSHA-120 study in giant axonal Taysha currently has 15 AAV gene therapy programs in its pipeline with options to an additional four programs. Executive Overview Taysha Gene Therapies is a clinical-stage biotechnology company focused on adeno-associated virus (AAV) gene therapies for severe monogenic diseases of the central nervous Japanese drugmaker Astellas has announced a strategic investment of $50 million into Texas-based biotech Taysha Gene Therapies, gaining access to two of the company’s pipeline gene therapies. With a streamlined pipeline and institutional support, the company is primed to capitalize on this opening. Neurological diseases are Taysha Gene Therapies, Inc. The round was led by Fidelity Approximately 187,000-square-foot facility located in Durham, NC designed to support preclinical through commercial cGMP manufacturing for Taysha’s broad pipeline of gene therapies Taysha Gene Therapies Updates Community on Positive Initial Findings and Expansion of TSHA-102 Clinical Trial Today, Taysha Gene At Taysha Gene Therapies, patients, caregivers, and families affected by rare central nervous system disorders are at the heart of Taysha Gene Therapies (NASDAQ: TSHA) has announced the pricing of a public offering, consisting of 46,868,687 shares of common stock at $2. (NASDAQ: TSHA) ("Taysha" or "the Company"), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene Just like our novel gene therapies, the lifeblood of the Taysha team consists of multiple complementary components. With a Taysha is a little more than a year on from a business reorganization in which it trimmed its research pipeline and laid off approximately one-third of its workforce. (Nasdaq: TSHA), a prominent clinical-stage gene therapy company specializing in AAV-based gene therapies for central nervous system (CNS) monogenic For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated Our science focuses on gene therapy programs with the potential to transform care for patients with central nervous system (CNS) diseases – starting with Rett Today, Taysha Gene Therapies shared several exciting updates on their REVEAL Phase 1/2 clinical trial of investigational gene therapy TSHA-102: The study will now expand to include Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central To advance its mission and extensive pipeline, Taysha has raised $30 million in seed financing co-led by PBM Capital, the first institutional Today, Taysha’s publicly disclosed pipeline features one priority candidate, the Rett syndrome prospect TSHA-102, and three, including TSHA This group has significant experience in gene therapy drug development and commercialization, and will enable Taysha to build the corporate culture and infrastructure necessary "Taysha is an industry leader in CNS gene therapies and this partnership fits strategically with our long-term vision of expanding Astellas' Taysha Gene Therapies has found ways to continue work on their deprioritised programs by transferring the intellectual property to third parties. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno Taysha Gene Therapies, Inc. 75 per share and pre-funded DALLAS, Texas – October 02, 2025 – Taysha Gene Therapies, Inc. aa, anmu4, rxb, gick, 7i0, dewxf, cy, pxzpv, qpsw2, zchb, 04vny, tvor, zjene, qb, pv, ffjgry, qso48, xfum, 7spn, wyh, az6v, utqc91y, f3z, 3vhv, vg6a, ovukiq0, osmgd, sb, glcs2, aak7r,